EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Clinical Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) and Detection of BCR-ABL Gene Mutations in Korean Patients with Chronic Myeloid Leukemia

Yong-Hak Sohn, Hyun-Sook Chi, Chan-Jeoung Park, Kyoo-Hyung Lee, Eul-Ju Seo

The Korean Journal of Hematology · 2005

DOI: 10.5045/kjh.2005.40.2.82 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Korean Journal of Hematology, 2005. Verfasst von Yong-Hak Sohn und 4 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Imatinib mesylate, the tyrosine kinase activity of the BCR-ABL fusion gene, induces a remarkable remission in chronic myeloid leukemia (CML) patients.However, resistance to imatinib has been observed in a significant proportion of subjects, with the point mutations of the BCR-ABL kinase domain clinically identified as a possible mechanism.The aim of this study was to investigate clinical resistance to imatinib in Korean CML patients, and search for the point mutation of the BCR-ABL gene.

Methods

The clinical data and cytogenetic results of thirty two CML patients, who were treated with imatinib, between Jan. 2002 and Aug. 2003, were evaluated.Mutational analyses for the point mutations of the BCR-ABL kinase domain in clinically resistant patients were tested using RT-PCR and direct sequencing methods.

Results

Complete hematological remission was obtained in all CML patients with a chronic phase and in 4 of 6 CML with accelerated or blast crisis.However, 4 patients (2 in the chronic phase and 2 with blast crisis) relapsed to blast crisis following continued treatment.A major cytogenetic response was observed in 67% of the chronic phase patients, but in 2, the Philadelphia chromosomes reemerged in a follow-up chromosome study.Mutational analyses showed point mutations in the 351st amino acid of the BCR-ABL kinase domain in 2 patients: M351T, which has previously been reported in many studies, and a novel substitution, M351L.

Conclusion

The frequency of imatinib resistance in Koreans was similar to that found in well-controlled western studies.Point mutations of the BCR-ABL kinase domain were detected in two patients.Further studies, with more sensitive methods and a greater number of patients will help reveal other mechanisms of imatinib resistance and establish more effective treatment plans.(Korean J Hematol 2005;40:82-92.)

Zitieren

APA

Sohn, Y., Chi, H., Park, C., Lee, K., & Seo, E. (2005). Clinical Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) and Detection of BCR-ABL Gene Mutations in Korean Patients with Chronic Myeloid Leukemia. The Korean Journal of Hematology. https://doi.org/10.5045/kjh.2005.40.2.82

Vancouver

Sohn Y, Chi H, Park C, Lee K, Seo E. Clinical Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) and Detection of BCR-ABL Gene Mutations in Korean Patients with Chronic Myeloid Leukemia. The Korean Journal of Hematology. 2005. doi:10.5045/kjh.2005.40.2.82

BibTeX
@article{Sohn2005,
  author = {Sohn, Yong-Hak and Chi, Hyun-Sook and Park, Chan-Jeoung and Lee, Kyoo-Hyung and Seo, Eul-Ju},
  title = {Clinical Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) and Detection of BCR-ABL Gene Mutations in Korean Patients with Chronic Myeloid Leukemia},
  journal = {The Korean Journal of Hematology},
  year = {2005},
  doi = {10.5045/kjh.2005.40.2.82}
}
Kostenlos starten →